The results suggest that patients with metastatic colorectal cancer resistant to cetuximab and those with concomitant HER-2 amplification and ineffective clinical treatment may benefit from the combination of HER-2 inhibitors and EGFR inhibitors [135]. Here, ERBB2 is linked to metastatic colorectal cancer.